Affimed (AFMD) Swings to Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- US stock futures rise ahead of jobs data; chip, software shares rally
- Oil prices drop as investors weigh potential Hormuz deal between Iran and Gulf states
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Why a solid NFP report could spark a stock selloff, according to JPMorgan
- 'Sell America' trade returns as Fed, yen risks mount
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Nielsen to acquire DoubleVerify in merger deal
- Apollo to acquire easyJet for £5.7B in cash deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Affimed Reports Financial Results for Third Quarter 2015
November 10, 2015 7:30 AM ESTHEIDELBERG, Germany, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended September 30, 2015.
"Over this past quarter, we have made progress on several fronts. In terms of pipeline, we are currently enrolling patients in the amended AFM11 study. We also presented data for the first time of our NK- and T-cell engaging TandAbs against a solid tumor target, variant III of the Epidermal Growth Factor Receptor," said Dr. Adi Hoess, CEO of Affimed. "In addition, the recent... More
Affimed Reports Financial Results for Third Quarter 2015
November 10, 2015 7:30 AM ESTHEIDELBERG, Germany, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, today reported financial results for the quarter ended September 30, 2015.
"Over this past quarter, we have made progress on several fronts. In terms of pipeline, we are currently enrolling patients in the amended AFM11 study. We also presented data for the first time of our NK- and T-cell engaging TandAbs against a solid tumor target, variant III of the Epidermal Growth Factor Receptor," said Dr. Adi Hoess, CEO of Affimed. "In addition, the recent... More
